AUTO-9

N/A

Report date: 2024/05/11 18:35:42

Base Information

Drug NameAUTO-9

Drug Alias NameAUTO-9AUTO9

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsInterleukin-3 receptor subunit alpha modulatorsC-Type lectin domain family 12 member A modulators

TargetsMyeloid cell surface antigen CD33Interleukin-3 receptor subunit alphaC-Type lectin domain family 12 member A

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAutolus Therapeutics Plc

China Registration ClassN/A

Develop Information

Active CompaniesAutolus Therapeutics Plc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A